Phathom Pharmaceuticals (PHAT) Return on Equity (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.0%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (down 1.0% YoY), and the FY2025 annual result was 0.01%, down 1.0% from the prior year.
• Return on Equity slipped to 0.0% in Q1 2026 per PHAT's latest filing, from 0.01% in the prior quarter.
• Over five years, Return on Equity peaked at 20.44% in Q3 2023 and troughed at 0.1% in Q2 2022.
• A 5-year average of 1.22% and a median of 0.02% in 2024 frame the typical range for Return on Equity.
• The sharpest annual moves came in 2023 and 2024: Return on Equity jumped 2033 bps in 2023, then plunged 2042 bps in 2024.
• A 5-year view of Return on Equity shows it stood at 0.04% in 2022, then advanced by 14 bps to 0.04% in 2023, then tumbled by 66 bps to 0.02% in 2024, then plunged by 66 bps to 0.01% in 2025, then fell by 21 bps to 0.0% in 2026.
• Business Quant data shows PHAT's Return on Equity at 0.0% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.